Stroke prevention in atrial fibrillation

被引:11
作者
Lip, Gregory Y. H. [1 ,2 ,3 ]
Gue, Ying [1 ,2 ]
Zhang, Juqian [1 ,2 ]
Chao, Tze-Fan [4 ,5 ,6 ]
Calkins, Hugh [7 ]
Potpara, Tatjana [8 ,9 ]
机构
[1] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England
[2] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
[3] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
[4] Taipei Vet Gen Hosp, Dept Med, Div Cardiol, Taipei, Taiwan
[5] Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan
[6] Natl Yang Ming Univ, Cardiovasc Res Ctr, Taipei, Taiwan
[7] Johns Hopkins Med Inst, Dept Cardiol, Baltimore, MD 21205 USA
[8] Univ Belgrade, Sch Med, Belgrade, Serbia
[9] Clin Ctr Serbia, Cardiol Clin, Belgrade, Serbia
关键词
MOBILE HEALTH TECHNOLOGY; BLEEDING RISK-ASSESSMENT; WILLEBRAND-FACTOR LEVELS; ANTITHROMBOTIC THERAPY; ORAL ANTICOAGULANTS; ASIAN PATIENTS; APPENDAGE CLOSURE; ADVERSE EVENTS; STRATIFICATION; OUTCOMES;
D O I
10.1016/j.tcm.2021.10.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atrial fibrillation (AF) is the commonest sustained cardiac rhythm disorder associated with an increased risk of stroke and systemic embolic events. The prevention of stroke using oral anticoagulants has been a pivotal component of AF management. The purpose of this review is to summarize recent advances in the treatment and prevention of stroke in AF over the last 5 years. We performed a comprehensive structured literature search using MEDLINE for publications from 11th March 2015 through to 31st December 2020. We focused mainly on primarily published research articles and systematic reviews including updates in different international guidelines. We found that improved awareness and detection of AF and use of clinical risk stratification are central to the identification of patients at risk of stroke who would benefit from oral anticoagulation. The recommendation of non-vitamin K antagonist oral anticoagulants over warfarin in both efficacy and safety perspective is represented in all international guidelines. Beyond stroke prevention, there is a move to more holistic or integrated care management of AF, which has been shown to improve outcomes. We conclude that stroke prevention remains a dominant part of the management of patients with AF. Not all stroke risk factors carry equal weight, and many require additional scrutiny (e.g. severity of CAD, type of diabetes, duration of hypertension). The utilization of clinical risk scores to help decision-making should take into account that these scores are mere simplification tools to aid decision-making and the additional clinical benefit with more complex risk scores and addition of biomarkers is limited. Also, stroke and bleeding risks are dynamic and require regular review. Instead of arbitrarily categorizing patients into (artificial) low, moderate, and high stroke risk strata, anticoagulation should be offered to all patients with AF unless they are low risk with no risk factors for stroke. Stroke prevention is also part of the proactive, integrated care approach to holistic management of patients with AF, which can be simplified in the ABC (Atrial fibrillation Better Care) pathway: `A' Avoid stroke/Anticoagulation; `B' Better symptom management emphasising patient-centred symptom directed decisions on rate or rhythm control strategies; and `C' refers to Cardiovascular risk and comorbidity optimization, including lifestyle changes and attention to patient values and preferences, as well as the psychological morbidity associated with AF. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:501 / 510
页数:10
相关论文
共 72 条
[31]   Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation [J].
Hart, Robert G. ;
Pearce, Lesly A. ;
Aguilar, Maria I. .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (12) :857-867
[32]  
Hijazi Z., 2016, Eur Heart J
[33]  
Hindricks G, 2020, EUR HEART J
[34]   Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study [J].
Hippisley-Cox, Julia ;
Coupland, Carol ;
Brindle, Peter .
BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
[35]   Sex and Race Differences in the Association of Incident Ischemic Stroke With Risk Factors [J].
Howard, Virginia J. ;
Madsen, Tracy E. ;
Kleindorfer, Dawn O. ;
Judd, Suzanne E. ;
Rhodes, J. David ;
Soliman, Elsayed Z. ;
Kissela, Brett M. ;
Safford, Monika M. ;
Moy, Claudia S. ;
McClure, Leslie A. ;
Howard, George ;
Cushman, Mary .
JAMA NEUROLOGY, 2019, 76 (02) :179-186
[36]   Refining Stroke Prediction in Atrial Fibrillation Patients by Addition of African-American Ethnicity to CHA2DS2-VASc Score [J].
Kabra, Rajesh ;
Girotra, Saket ;
Sarrazin, Mary Vaughan .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (05) :461-470
[37]   Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation [J].
Lee, So-Ryoung ;
Choi, Eue-Keun ;
Park, Sang-Hyun ;
Jung, Jin-Hyung ;
Han, Kyung-Do ;
Oh, Seil ;
Lip, Gregory Y. H. .
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (05) :415-423
[38]   One-year risks of stroke and mortality in patients with atrial fibrillation from different clinical settings: The Gulf SAFE registry and Darlington AF registry [J].
Li, Yan-Guang ;
Miyazawa, Kazuo ;
Wolff, Andreas ;
Zubaid, Mohammad ;
Alsheikh-Ali, Alawi A. ;
Sulaiman, Kadhim ;
Lip, Gregory Y. H. .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 274 :158-162
[39]   Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation [J].
Lip, Gregory Y. H. ;
Lane, Deirdre ;
Van Walraven, Carl ;
Hart, Robert G. .
STROKE, 2006, 37 (09) :2294-2300
[40]   Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report [J].
Lip, Gregory Y. H. ;
Banerjee, Amitava ;
Boriani, Giuseppe ;
Chiang, Chern en ;
Fargo, Ramiz ;
Freedman, Ben ;
Lane, Deirdre A. ;
Ruff, Christian T. ;
Turakhia, Mintu ;
Werring, David ;
Patel, Sheena ;
Moores, Lisa .
CHEST, 2018, 154 (05) :1121-1201